Marinus Pharmaceuticals Management
Management criteria checks 3/4
Marinus Pharmaceuticals' CEO is Scott Braunstein, appointed in Aug 2019, has a tenure of 4.58 years. total yearly compensation is $3.13M, comprised of 18.9% salary and 81.1% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $505.04K. The average tenure of the management team and the board of directors is 3.3 years and 4.3 years respectively.
Key information
Scott Braunstein
Chief executive officer
US$3.1m
Total compensation
CEO salary percentage | 18.9% |
CEO tenure | 4.6yrs |
CEO ownership | 0.1% |
Management average tenure | 3.3yrs |
Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?
Nov 04Marinus Pharmaceuticals (MRNS) Investor Presentation - Slideshow
May 26We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely
Apr 14Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share Price
Mar 10CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$141m |
Sep 30 2023 | n/a | n/a | -US$134m |
Jun 30 2023 | n/a | n/a | -US$28m |
Mar 31 2023 | n/a | n/a | -US$35m |
Dec 31 2022 | US$3m | US$591k | -US$20m |
Sep 30 2022 | n/a | n/a | -US$14m |
Jun 30 2022 | n/a | n/a | -US$105m |
Mar 31 2022 | n/a | n/a | -US$91m |
Dec 31 2021 | US$4m | US$574k | -US$99m |
Sep 30 2021 | n/a | n/a | -US$88m |
Jun 30 2021 | n/a | n/a | -US$84m |
Mar 31 2021 | n/a | n/a | -US$76m |
Dec 31 2020 | US$4m | US$556k | -US$76m |
Sep 30 2020 | n/a | n/a | -US$74m |
Jun 30 2020 | n/a | n/a | -US$72m |
Mar 31 2020 | n/a | n/a | -US$69m |
Dec 31 2019 | US$2m | US$305k | -US$54m |
Sep 30 2019 | n/a | n/a | -US$49m |
Jun 30 2019 | n/a | n/a | -US$46m |
Mar 31 2019 | n/a | n/a | -US$43m |
Dec 31 2018 | US$210k | n/a | -US$37m |
Compensation vs Market: Scott's total compensation ($USD3.13M) is above average for companies of similar size in the US market ($USD2.19M).
Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.
CEO
Scott Braunstein (60 yo)
4.6yrs
Tenure
US$3,131,996
Compensation
Dr. Scott N. Braunstein, M.D., serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He served as Director at Protara Therapeutics, Inc. (formerly known as ArTara Therapeutics, In...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Chairman | 4.6yrs | US$3.13m | 0.10% $ 505.0k | |
COO, CFO & Treasurer | 2.9yrs | US$1.43m | 0.023% $ 112.1k | |
Chief Medical Officer | 4.4yrs | US$1.52m | 0.023% $ 109.3k | |
Chief Scientific Officer | no data | no data | no data | |
Senior VP of Investor Relations | less than a year | no data | no data | |
Senior VP | 3.8yrs | no data | 0.0057% $ 27.4k | |
Director of Corporate Communications & Investor Relations | less than a year | no data | no data | |
Chief Regulatory & Quality Assurance Officer | no data | no data | no data | |
Chief Business Officer | no data | no data | no data | |
Chief Commercial Officer | 3.3yrs | no data | 0.018% $ 84.8k | |
Senior Vice President of Chemistry | no data | no data | no data | |
Senior Vice President of Development | no data | no data | no data |
3.3yrs
Average Tenure
60yo
Average Age
Experienced Management: MRNS's management team is considered experienced (3.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Chairman | 5.5yrs | US$3.13m | 0.10% $ 505.0k | |
Lead Independent Director | 15.3yrs | US$210.31k | 0.025% $ 122.2k | |
Independent Director | 4.3yrs | US$200.64k | 0.0037% $ 17.6k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 7.5yrs | US$189.47k | 0.0044% $ 21.4k | |
Independent Director | 3yrs | US$193.81k | 0.0050% $ 24.2k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3.7yrs | US$195.64k | 0.0031% $ 14.8k | |
Independent Director | 1.2yrs | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
4.3yrs
Average Tenure
61yo
Average Age
Experienced Board: MRNS's board of directors are considered experienced (4.3 years average tenure).